Melanotan 2 product tests and clinical trials
The product papers ask what the material contains. The human trials ask what a known preparation did. Both questions deserve an answer.
Product identification: 2015, 2021 and 2024
The 2015 contents analysis compared measured Melanotan II with the quantity claimed by online shops. Its 4.32–8.84 mg range fell below the claimed 10 mg, and products from two of three shops contained unidentified impurities at 4.1–5.9%.
In the 2021 LC-HRMS investigation, forensic toxicologists characterized Melanotan II and bremelanotide in eight unknown confiscated samples. Accurate-mass and fragmentation analysis allowed identification without reference standards. The 2024 identification paper likewise addresses seized and online-sold material in an unregulated supply chain.
The forensic ingenuity impresses me. It separates an actual molecule from a suggestive name, which is a considerable achievement. The achievement still ends at the sample: it supplies no certificate for the next untested batch and no answer about long-term safety.
Operation Resistance placed Melanotan II among falsified biopharmaceutical injectables. A review of falsified biotechnology drugs describes the broader problems of wrong active ingredients, wrong quantities, absent active ingredients and impurities. That is the commercial setting in which the old trial results now circulate.
The pigmentation pilot
The 1996 Phase I pilot enrolled three healthy men. It was single-blind and placebo-controlled, and recorded increased facial, upper-body and buttock pigmentation in two of three subjects after five exposures across two weeks, without UV exposure. Mild nausea occurred, and spontaneous erections lasted 1–5 hours.
The study established biological activity in that small group. I credit the modest result; the much larger claims built on top of it still need their own evidence. The published human programme never developed a completed Phase II or Phase III safety record for Melanotan II.
The erectile-dysfunction crossover study
In the 1998 double-blind crossover trial, 10 men with psychogenic erectile dysfunction received Melanotan II and placebo at separate visits. Clinically apparent erections occurred in 8 of 10 men after Melanotan II. Mean duration of greater than 80% tip rigidity was 38.0 minutes with the peptide versus 3.0 minutes with placebo.
That measurement is narrower than “erections averaged 38 minutes”: it specifies a rigidity threshold. That is the kind of precision I will defend, however untidy the sentence becomes. The trial also recorded transient nausea, stretching and yawning, and its selected population limits how far the result travels.
The history of melanocortin therapeutics and the PT-141 development paper trace the related sexual-function programme. Bremelanotide became a separate medicine; its later approval supplies no approval for Melanotan II.
Food seeking in male mice
The 2022 nucleus-accumbens experiment placed Melanotan II directly into a brain region in male mice. Food consumption fell, as did responding to gain food, without conditioned taste aversion or a change in metabolic rate. “Wanting food” and “burning more energy” came apart in this experiment.
The earlier rat aversion study had different results under different conditions: reduced food intake accompanied learned aversion. I distrust a weight-loss pitch assembled from only the friendliest animal result. Both are animal work, and neither establishes a human weight-loss treatment.
Female-rat behaviour and the separate sunlight programme
In hormone-primed, ovariectomized female rats, intravenous Melanotan II increased solicitation behaviours during paced mating without changing lordosis, the mating posture. The distinction between motivation and posture is useful; translating it into a promise about human desire would go much further than the experiment.
The larger sunlight programme used afamelanotide. Its Phase 3 EPP trials and 115-patient observational follow-up concern a different drug and a defined photosensitivity disorder. The tanning page gives that programme room of its own.